Health ❯ Healthcare ❯ Pharmaceuticals

Drug Development

Clinical Trials Obesity Treatments Monoclonal Antibodies Alzheimer's Disease Combination Therapy Eli Lilly Oncology Immunotherapy Novo Nordisk GLP-1 Drugs

Acadia’s Alzheimer’s Psychosis Drug Misses Mid‑Stage Goal

The result increases doubt over whether the drug can show a replicable benefit in phase‑3 trials.

Amgen’s Dazodalibep Meets Primary Goal in Phase 3 Sjögren’s Trial

Iambic Therapeutics Files for Nasdaq IPO to Fund AI Cancer Pipeline

CHMP Recommends Expanding Enhertu Label to Add Adjuvant Use

Securities Suit Targets Capricor Over FDA Findings on Trial Analysis

Xenon Submits NDA for Epilepsy Drug as Psychiatric Trials Pause After Safety Signals

Gotistobart Extends Survival in Early PRESERVE‑003 Update

Amivantamab Plus Chemotherapy Shows Longest Survival for EGFR Exon 20 Insertion Lung Cancer

FDA Approves Isembyld, First Muscle‑Directed Therapy for Spinal Muscular Atrophy

B7‑H3 Antibody‑Drug Conjugates Cut Death Risk by Half in Relapsed Small‑Cell Lung Cancer

AstraZeneca’s Etcamah Falls Short in Pivotal SERENA‑4 Breast Cancer Trial

AI-Designed Drug Rentosertib Lowers Biological-Age Signals in Small Trial

AstraZeneca's Tozorakimab Cuts COPD Flare‑Ups in Two Phase 3 Trials

Novartis’ Del‑Desiran Misses Phase III and Triggers Large Share Selloff

FDA Approves Lisraya for Adult Dermatomyositis

FDA Clears Pancreatic Drug That Shows Early Promise in RAS‑Mutant Lung Cancer

Ultragenyx Phase 3 Angelman Drug Fails to Show Benefit

Lilly to Buy Merida Biosciences for Up to $2.875 Billion

Novartis Moves to File Oral MS Drug After Phase‑3 Win as Separate CAR‑T Trials Are Paused

FDA Expands Mounjaro Label to Include Cardiovascular Risk Reduction